Startups
ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers
On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).
On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).
Overview
Location
United States, New York
Employees
5001-10000
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 23, 2007 | AstraZeneca ups the biotech ante | Now that AstraZeneca has made the bold — or impulsive — decision to snap up MedImmune for $15.6 billion in cash, one big question is whether the U.K. pharmaceutical giant has kicked Big Pharma’s appetite for biotech acquisitions into high g... |
Reviews 0
FAQ about ImClone Systems
What has the press written about ImClone Systems?
Parsers VC has collected 2 articles mentioning ImClone Systems, among them “AstraZeneca ups the biotech ante” (Apr 23, 2007).
Is ImClone Systems still active?
ImClone Systems is probably closed: its latest activity on Parsers VC dates from Mar 23, 2011.